Clinical Trial Detail

NCT ID NCT01434602
Title Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

malignant glioma

gliosarcoma

glioblastoma multiforme

astrocytoma

oligodendroglioma

mixed oligodendroglioma-astrocytoma

Therapies

Everolimus + Sorafenib

Age Groups: adult

No variant requirements are available.